Compass therapeutics reports 2024 financial results and provides corporate update

Top-line phase 2/3 data readout for companion-002, evaluating tovecimig (ctx-009 - a dll4 x vegf-a bispecific antibody) in patients with biliary tract cancer (btc), is on track for the end of the first quarter 2025. supported initiation of an investigator sponsored study (ist) evaluating tovecimig in patients with btc in the first-line setting, with patient dosing expected in the first quarter 2025.
CMPX Ratings Summary
CMPX Quant Ranking